Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Ensemble Therapeutics announces initiation of drug discovery collaboration with Alexion subsidiary

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the potential to modulate targets typically addressed by biologics, today announced the initiation of a drug discovery collaboration with a subsidiary of Alexion Pharmaceuticals, Inc., the global biopharmaceutical company focused on developing and commercializing life-transforming therapies for patients with life-threatening, ultra-rare disorders.

18 Jul 2013

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

Filariasis refers to a group of diseases caused by parasitic worms, which are transmitted by blood feeding insects. Two species infect the lymphatic and blood systems causing lymphatic filariasis, which in some people can lead to gross swelling of the limbs and 'elephantiasis'.

18 Jul 2013

Scientists develop statistical models to predict which drug is best for specific disease

Medicines that are personally tailored to your DNA are becoming a reality, thanks to the work of U.S. and Chinese scientists who developed statistical models to predict which drug is best for a specific individual with a specific disease.

17 Jul 2013

Ipsen, Harvard initiate collaboration to discover, develop botulinum toxins for neurologic diseases

Ipsen announced today that it has initiated a research and development collaboration on novel engineered botulinum toxins with Harvard Medical School.

15 Jul 2013

Global recruitment drive to bring best cancer experts to Manchester now underway

A global recruitment drive to bring 20 of the world's best cancer experts and their teams to Manchester, in the United Kingdom, is now underway.

From The University of Manchester 12 Jul 2013

Research opens door to better understanding of inner-ear development process, potential treatments

Indiana University scientists have transformed mouse embryonic stem cells into key structures of the inner ear. The discovery provides new insights into the sensory organ's developmental process and sets the stage for laboratory models of disease, drug discovery and potential treatments for hearing loss and balance disorders.

12 Jul 2013

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration of Australia has approved KALYDECO (ivacaftor) for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

10 Jul 2013

Boehringer Ingelheim signs multi-year renewal agreement to NextBio Research Platform

NextBio, whose Big Data technology enables users to apply genomic data from disparate sources in novel and useful ways across life sciences research, today announced that Boehringer Ingelheim has signed a multi-year renewal agreement to the NextBio Research Platform.

9 Jul 2013

Viewpoints: Health care's hidden consensus; Examining the fee-for-service payment system; Alternative medicine's allure

The politicians' consensus is that health care reform shouldn't alter or disrupt the way the majority of Americans get their insurance today. ... The policy consensus, though, is that the status quo is actually the problem, and that it deserves to be threatened, undermined and replaced as expeditiously as possible. Wonks of the left and right disagree on what that replacement should look like. But they're united in regarding employer-provided coverage as an unsustainable relic (Ross Douthat, 7/6).

9 Jul 2013

FORMA Therapeutics, CRT partner to discover therapeutic drug candidates against DUBs

FORMA Therapeutics and Cancer Research Technology, Ltd., the commercialization company of Cancer Research UK, announced today a bold research initiative to discover innovative tools, technologies and therapeutic drug candidates against a variety of protein homeostasis regulators called, deubiquitinating enzymes.

9 Jul 2013

MerTK inhibition in leukocytes decreases tumor growth and metastasiss

The tyrosine kinase MerTK plays a prominent role in the body's immune response. MerTK signaling helps "calm" the body's first line of immunity, the macrophage, while it performs the routine duties - clearing cells that die and healing damaged tissue.

9 Jul 2013

p53 restoration of function drug candidate: an interview with Dr. Wayne Danter, MD, FRCPC President and CEO of Critical Outcome Technologies

COTI-2 is a computer-designed small molecule that was discovered by our artificial intelligence drug discovery platform called CHEMSAS.

8 Jul 2013

Seattle researchers map critical molecules that regulate inflammation during flu infection

The influenza virus' ability to mutate quickly has produced new, emerging strains that make drug discovery more critical than ever. For the first time, researchers at Seattle BioMed, along with collaborators at the University of California, San Diego School of Medicine, St. Jude Children's Research Hospital and the University of Washington, have mapped how critical molecules regulate both the induction and resolution of inflammation during flu infection.

6 Jul 2013

Liverpool School of Tropical Medicine receives US$ 10 million to continue research against human filariasis

Liverpool School of Tropical Medicine (LSTM) has received US$ 10 million from the Bill & Melinda Gates Foundation to continue their breakthrough drug discovery and development research against human filariasis - parasitic worm infections which cause river blindness and elephantiasis, some of the world’s most debilitating diseases affecting up to 150 million people in 83 countries throughout the tropics.

1 Jul 2013

University of Manchester, F2G to develop new antifungal drug for fungal infections

F2G Ltd and The University of Manchester Announce a new €6.1million project to develop new antifungal agents to treat resistant fungal infections.

26 Jun 2013

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Seattle Genetics, Inc. today announced that it has entered into a new antibody-drug conjugate (ADC) collaboration with Bayer HealthCare (Bayer). Under the latest relationship, Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics' auristatin-based ADC technology with antibodies to several oncology targets.

25 Jun 2013

Newly developed palm-sized microarray platform could enable faster, more efficient drug discovery

A new palm-sized microarray that holds 1,200 individual cultures of fungi or bacteria could enable faster, more efficient drug discovery, according to a study published in mBio-, the online open-access journal of the American Society for Microbiology.

25 Jun 2013

UT candidate wins AHA fellowship to support research in cardiovascular, stroke discoveries

University of Texas at San Antonio biomedical engineering Ph.D. candidate Anand Srinivasan has been awarded a $25,000, one-year doctoral fellowship from the American Heart Association (AHA).

20 Jun 2013

Moffitt Cancer Center, Advinus Therapeutics form strategic partnership

Moffitt Cancer Center announced a strategic partnership with Advinus Therapeutics to advance its discoveries to the clinics. Two promising targeted cancer therapies (Rb:Raf-1 disruptor and ROCK inhibitor) developed by Moffitt scientists are selected as the first set.

18 Jun 2013

NGM, MedImmune partner to develop novel therapeutics for treatment of diabetes and obesity

NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell program for the treatment of type 2 diabetes and obesity.

17 Jun 2013

Drug Discovery News and Research

Further Reading

Ensemble Therapeutics announces initiation of drug discovery collaboration with Alexion subsidiary

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

Scientists develop statistical models to predict which drug is best for specific disease

Ipsen, Harvard initiate collaboration to discover, develop botulinum toxins for neurologic diseases

Global recruitment drive to bring best cancer experts to Manchester now underway

Research opens door to better understanding of inner-ear development process, potential treatments

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Boehringer Ingelheim signs multi-year renewal agreement to NextBio Research Platform

Viewpoints: Health care's hidden consensus; Examining the fee-for-service payment system; Alternative medicine's allure

FORMA Therapeutics, CRT partner to discover therapeutic drug candidates against DUBs

MerTK inhibition in leukocytes decreases tumor growth and metastasiss

p53 restoration of function drug candidate: an interview with Dr. Wayne Danter, MD, FRCPC President and CEO of Critical Outcome Technologies

Seattle researchers map critical molecules that regulate inflammation during flu infection

Liverpool School of Tropical Medicine receives US$ 10 million to continue research against human filariasis

University of Manchester, F2G to develop new antifungal drug for fungal infections

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Newly developed palm-sized microarray platform could enable faster, more efficient drug discovery

UT candidate wins AHA fellowship to support research in cardiovascular, stroke discoveries

Moffitt Cancer Center, Advinus Therapeutics form strategic partnership

NGM, MedImmune partner to develop novel therapeutics for treatment of diabetes and obesity

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News